Immunovant News

Immunovant (IMVT) Gets a Buy From Piper Sandler

TipRanksApr 26 19:52

Buy Rating Affirmed for Immunovant on Strong Drug Development Prospects and Efficacy Confidence

TipRanksApr 22 17:55

Immunovant Analyst Ratings

BenzingaMar 28 18:48

Truist Securities Reiterates Buy on Immunovant, Maintains $48 Price Target

BenzingaMar 26 00:11

Immunovant Analyst Ratings

BenzingaMar 26 00:10

Buy Rating for Immunovant Amidst Strong Market Position and Promising Batoclimab Trials

TipRanksMar 22 01:15

Immunovant Analyst Ratings

BenzingaMar 13 20:36

Goldman Sachs Initiates Coverage On Immunovant With Buy Rating, Announces Price Target of $50

BenzingaMar 13 20:38

Immunovant Analyst Ratings

BenzingaFeb 20 19:30

Wolfe Research Initiates Coverage On Immunovant With Outperform Rating, Announces Price Target of $55

BenzingaFeb 15 19:40

Immunovant Analyst Ratings

BenzingaFeb 15 19:38

Buy Rating Affirmed on Immunovant's Promising Pipeline and Strategic Clinical Advancements

TipRanksFeb 15 14:16

Analysts Are Bullish on Top Healthcare Stocks: Immunovant (IMVT), 4D Molecular Therapeutics (FDMT)

TipRanksFeb 13 19:20

Buy Rating Affirmed on Immunovant Amidst Strategic Growth and Pipeline Strength

TipRanksFeb 13 18:03

Immunovant (IMVT) Poised for Growth: A Buy Rating Backed by Strong Pipeline and Upcoming Catalysts

TipRanksFeb 13 17:59

Immunovant's Buy Rating: Market Opportunities and Positive Trial Outcomes for Batoclimab

TipRanksFeb 6 04:55

Stifel Nicolaus Keeps Their Buy Rating on Immunovant (IMVT)

TipRanksDec 26, 2023 10:05

Analysts' Top Healthcare Picks: Hookipa Pharma (HOOK), Immunovant (IMVT)

TipRanksDec 25, 2023 13:40

Stifel Nicolaus Sticks to Their Buy Rating for Immunovant (IMVT)

TipRanksDec 21, 2023 20:26

Immunovant's Strong Phase 2 Results and Positive Outlook Prompt Buy Rating

TipRanksDec 21, 2023 19:56